Name | Title | Contact Details |
---|
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Dauntless Pharmaceuticals, Inc is a San Diego, CA-based biopharmaceutical company. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets. In contrast, Dauntless uses a one-asset, one-company model.
Hepalife Technologies is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
3B Medical, Inc. Focused on innovative solutions in sleep therapy, with an emphasis on improving patient compliance with design focused on patient comfort. NEW! Introducing iCode for Android & iPhone. (For use with all RESmart CPAP & Auto-CPAP mod...